title: Transepithelial transport of biperiden hydrochloride in Caco-2 cell monolayers.
abstract: The aim of this research has been to determine the biperiden hydrochloride permeability in Caco-2 model, in order to classify it based on the Biopharmaceutics Classification System (BCS). The World Health Organization (WHO) as well as many other authors have provisionally assigned the drug as BCS class I (high solubility-high permeability) or III (high solubility-low permeability), based on different methods. We determined biperiden BCS class by comparing its permeability to 5 pre-defined compounds: atenolol and ranitidine hydrochloride (low permeability group) and metoprolol tartrate, sodium naproxen and theophylline (high permeability group). Since biperiden permeability was higher than those obtained for high permeability drugs, we classified it as a BCS class I compound. On the other hand, as no differences were obtained for permeability values when apical to basolateral and basolateral to apical fluxes were studied, this drug cannot act as a substrate of efflux transporters. As a consequence of our results, we suggest that the widely used antiparkinsonian drug, biperiden, should be candidate for a waiver of in vivo bioequivalence studies.
authors.affiliation: Instituto Nacional de Medicamentos (INAME), Departamento de Farmacología, Av. Caseros 2161 (1264), Buenos Aires, Argentina. Electronic address: iabalos@anmat.gov.ar.
authors.forename: Ivana S
authors.initials: IS
authors.lastname: Abalos
authors.affiliation: Instituto Nacional de Medicamentos (INAME), Departamento de Farmacología, Av. Caseros 2161 (1264), Buenos Aires, Argentina.
authors.forename: Yanina I
authors.initials: YI
authors.lastname: Rodríguez
authors.affiliation: Instituto Nacional de Medicamentos (INAME), Departamento de Farmacología, Av. Caseros 2161 (1264), Buenos Aires, Argentina.
authors.forename: Verónica
authors.initials: V
authors.lastname: Lozano
authors.affiliation: Instituto Nacional de Medicamentos (INAME), Departamento de Farmacología, Av. Caseros 2161 (1264), Buenos Aires, Argentina.
authors.forename: Marina
authors.initials: M
authors.lastname: Cereseto
authors.affiliation: Instituto Nacional de Medicamentos (INAME), Departamento de Farmacología, Av. Caseros 2161 (1264), Buenos Aires, Argentina.
authors.forename: Maria V
authors.initials: MV
authors.lastname: Mussini
authors.affiliation: Instituto Nacional de Medicamentos (INAME), Departamento de Farmacología, Av. Caseros 2161 (1264), Buenos Aires, Argentina.
authors.forename: Marta E
authors.initials: ME
authors.lastname: Spinetto
authors.affiliation: Instituto Nacional de Medicamentos (INAME), Departamento de Farmacología, Av. Caseros 2161 (1264), Buenos Aires, Argentina.
authors.forename: Carlos
authors.initials: C
authors.lastname: Chiale
authors.affiliation: Instituto Nacional de Medicamentos (INAME), Departamento de Farmacología, Av. Caseros 2161 (1264), Buenos Aires, Argentina.
authors.forename: Guido
authors.initials: G
authors.lastname: Pesce
mesh_terms: D000978:Antiparkinson Agents / Q000145:classification / Q000378:metabolism*; D001692:Biological Transport; D001702:Biopharmaceutics / Q000145:classification; D001712:Biperiden / Q000145:classification / Q000378:metabolism*; D018938:Caco-2 Cells; D006801:Humans; D010539:Permeability; D012995:Solubility
chemical_list: D000978:Antiparkinson Agents; D001712:Biperiden